Abstract
While surgical resection is the most effective treatment for gallbladder cancer, most of these cancers are not resectable at the time of diagnosis, and therefore, chemotherapy serves as the primary therapy in many cases. However, to date, there is no standard chemotherapy for this cancer. We report a case of advanced gallbladder cancer for which the anticancer drug S-1 was effective. The patient was a 53-year-old woman who presented with a huge ovarian tumor. On workup, all abdominal images revealed the presence of advanced gallbladder cancer that had invaded the liver. Because the gallbladder formed a relatively hard and swollen mass involving the omentum, as revealed during exploration, the surgical resection of the gallbladder was not possible at that time, and only hysterectomy and bilateral salpingo-oophorectomy were performed. She started on the anticancer drug S-1 just after this operation. S-1 is a prodrug of 5-fluorouracil (5-FU), and contains 5-chloro-2-4-dihydroxypyridine (CDHP), an inhibitor of dihydropyrimidine dehydrogenase (DPD) that rapidly degrades 5-FU. Eight months after the first operation, radical cholecystectomy was performed. Pathologically, the tumor was diagnosed as an adenocarcinoma of the gallbladder, and no evidence of liver invasion was found. Intratumoral gene expression analysis of the resected gallbladder revealed significantly elevated DPD expression. We suggest that the rapid degradation of 5-FU mediated by this high DPD in our patient was significantly blocked by the CDHP in S-1, and that the efficacy of 5-FU was consequently maintained at the maximum level.
Similar content being viewed by others
References
Tatsumi K, Fukushima M, Shirasaka T, et al. (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Gann 78:748–755
Daher GC, Harris BE, Diasio RB (1990) Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 48: 189–222
de Bono JS, Twelves CJ (2001) The oral fluorinated pyrimidines. Invest New Drugs 19:41–59
Ichikawa W, Takahashi T, Suto K, et al. (2004) Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer 112:967–973
Miyoshi Y, Uemura H, Ishiguro H, et al. (2005) Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer. Prostate Cancer Prostatic Dis 8:260–265
Kuramochi H, Hayashi K, Uchida K, et al. (2006) Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 12:29–33
Misra S, Chaturvedi A, Misra NC, Sharma ID (2003) Carcinoma of the gallbladder. Lancet Oncol 4:167–176
Manfredi S, Benhamiche AM, Isambert N, et al. (2000) Trends in incidence and management of gallbladder carcinoma. A population-based study in France. Cancer 89:757–762
Grobmyer SR, Lieberman MD, Daly JM (2004) Gallbladder cancer in the twentieth century: Single institution’s experience. World J Surg 28:47–49
Miras S, Chaturvedi A, Misra NC (2006) Gallbladder cancer. Curr Treat Options Gastroenterol 9:95–106
Scanson J (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci U S A 83:8923–8925
Kuramochi H, Tenma N, Ohashi M (2003) A case of advanced gallbladder cancer with biliary tract stenosis which responded to TS-1 chemotherapy. Jpn J Cancer Chemother 30:1013–1016
Suzuki S, Harada N, Takeo Y, et al. (2004) A case of recurrent gallbladder cancer responding to combination chemotherapy of TS-1 and CDDP. Jpn J Cancer Chemother 31:1561–1563
Ueno H, Okusaka T, Ikeda M, et al. (2004) Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91:1769–1774
Aschele C, Lonardi S, Monfardini S (2002) Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 28:27–47
Fukushima M, Morita M, Ikeda K, et al. (2003) Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int J Mol Med 12:839–844
Kurebayashi J, Yamamoto Y, Udagawa K, et al. (2004) Establishment of enzyme-linked immunosorbent assays for thymidylate synthase and dihydropyriminide dehydrogenase in cancer tissues. Oncol Rep 11:973–979
Clark JL, Berger SH, Mittelman A, et al. (1987) Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrymidine chemotherapy. Cancer Treat Rep 71:261–265
Johnston PG, Fisher ER, Rockette HE, et al. (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2460–2467
Peters GJ, van der Wold CL, van Groeningen CJ, et al. (1994) Thymidylate synthase inhibition after administration of 5-fluorouracil with or without leucovorin in colon cancer patients: implication for treatment with 5-fluorouracil. J Clin Oncol 12: 2035–2042
Johnston CJ, Danenberg PV, Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407–1042
Salonga D, Danenberg KD, Johnson M, et al. (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322–1327
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kitajima, K., Kobayashi, S., Shiba, H. et al. Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene. Int J Clin Oncol 13, 545–551 (2008). https://doi.org/10.1007/s10147-008-0777-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-008-0777-z